Haas Jason

Haas Jason is listed in filings as Director at Ligand Pharmaceuticals Inc. This profile follows SEC Form 4 activity through Jun 15, 2026, including sale activity and purchase activity. Recent filings connect the profile to Ligand Pharmaceuticals Inc (LGND) and Syros Pharmaceuticals, Inc. (SYRS). The current snapshot covers public activity from Jun 18, 2024 to Jun 15, 2026. Reported amounts are shown as $886.3K to $51.6K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.